Mandie S. Gruber

Mandie S. White serves as a Contracting Officer within the National Cancer Institute (NCI), part of the National Institutes of Health under the Department of Health and Human Services, where she leads the acquisition of research and development services critical to advancing cancer diagnostics and precision medicine. She manages a portfolio of complex scientific contracts focused on translational research, laboratory infrastructure, and analytical technology development, ensuring alignment with NCI’s mission to accelerate breakthroughs in oncology. Her acquisitions are strategically designed to support high-capability research environments, often involving genomic analysis, molecular profiling, and bioinformatics platforms. Her primary contractor relationships center on Roche Diagnostics Corporation, reflecting a strong alignment with industry leaders in clinical diagnostics and life sciences innovation. She fosters long-term, performance-driven partnerships with vendors capable of delivering high-complexity, regulatory-compliant solutions, including assay development, instrument integration, and data analysis systems. These collaborations are typically structured as cost-reimbursement or fixed-price research contracts under the Federal Acquisition Regulation, emphasizing technical excellence and scientific rigor. White demonstrates an unwavering commitment to small business participation, with 100% of her acquisitions set aside for small businesses under FAR 19.5. She actively promotes equitable access to federal research funding by prioritizing small business concerns with proven expertise in life sciences R&D, ensuring diverse innovation pipelines and regional economic impact. Her procurement focus is exclusively aligned with NAICS 541715—Research and Development in the Physical, Engineering, and Life Sciences—encompassing contract research organizations, academic spin-offs, and specialized biotech firms delivering analytical tools, sequencing technologies, and computational biology services. Her domain expertise lies in procuring cutting-edge life sciences capabilities that directly enable NCI’s translational research goals.